Expansion of involvement from medical system operations into development
First written in FY2017. 9 of 30 entries say "Advanced", first in FY2018-Q2. Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1Loss of medical-related projectsAnnual report
「<System Development and Maintenance> Revenue declined to ¥180.845 million, down 19.5% year on year, due to the loss of development projects for the core clinical laboratory system in medical-related services and other factors.」
Despite the policy of expanding involvement in medical system development, the loss of development projects for the core clinical laboratory system caused system development and maintenance revenue to decline 19.5% year on year. - FY2025AdvancedAnnual report
「[System Development and Maintenance] Revenue rose to ¥409.345 million, up 52.2% year on year, due to revenue related to WITH-X® associated with development projects for the core clinical laboratory system in medical-related services, projects addressing regulatory revisions in the securities business, and other projects.」
Development of the core clinical laboratory system contributed to revenue in the medical field, and the expanded involvement in medical system development originating from system operations was reflected in a 52.2% year-on-year increase in development and maintenance revenue. - FY2025-H1AdvancedAnnual report
「<System Development and Maintenance> Revenue rose to ¥224.744 million, up 125.9% year on year, due to revenue related to WITH-X® associated with development projects for the core clinical laboratory system in medical-related services, projects addressing regulatory revisions in the securities business, and other projects.」
In the medical systems business, revenue from development of the core clinical laboratory system contributed to results for the interim consolidated accounting period, indicating progress from operations toward development and expansion of business with existing customers. - FY2024AdvancedAnnual report
「[System Development and Maintenance] Revenue rose to ¥268.889 million, up 76.8% year on year, due to increased development related to clinical laboratory systems and KIZUNA-X® (Note 3), among other factors.」
In the medical field, development of clinical laboratory systems increased, causing system development and maintenance revenue to rise 76.8% year on year. - FY2024-Q3AdvancedAnnual report
「<System Development and Maintenance> Revenue was ¥183.600 million, up 64.8% year on year, due mainly to the increase in clinical laboratory system development and maintenance support projects at subsidiaries.」
In the medical systems business, development of clinical laboratory systems increased, causing system development and maintenance revenue to rise 64.8% year on year. - FY2024-Q1Increase in medical tablet salesAnnual report
「<Machine Sales> Sales of tablet products for medical systems and other items resulted in revenue of ¥17.883 million, up 53.9% year on year.」
Sales of tablet products for medical systems rose to ¥17.883 million, up 53.9% year on year. - FY2023Continued loss of sales from medical system equipment replacementsAnnual report
「[Machine Sales] Revenue declined to ¥80.790 million, down 21.1% year on year, due to the loss of sales from medical system equipment replacements and other factors.」
The loss of sales from medical system equipment replacements continued through the full fiscal year, causing machine sales revenue to decline 21.1% year on year. - FY2023-Q3Continued revenue decline due to a change in the replacement timing of medical system equipmentAnnual report
「<Machine Sales> Revenue declined to ¥51.948 million, down 7.7% year on year, due to a change in the timing of revenue recognition for the replacement of medical system equipment and other factors.」
Due to a change in the replacement timing of medical system equipment, machine sales revenue declined to ¥51.948 million, down 7.7% year on year. - FY2023-Q2Revenue decline due to a change in the replacement timing of medical system equipmentAnnual report
「<Machine Sales> Revenue declined to ¥30.245 million, down 36.7% year on year, due to a change in the timing of revenue recognition for the replacement of medical system equipment and other factors.」
Due to a change in the replacement timing of medical system equipment, machine sales revenue declined to ¥30.245 million, down 36.7% year on year. - FY2023-Q1Increase in medical tablet salesAnnual report
「<Machine Sales> Sales of tablet products for medical systems and other items resulted in revenue of ¥11.620 million, up 88.9% year on year.」
Sales of tablet products for medical systems rose to ¥11.620 million, up 88.9% year on year. - FY2022Loss of medical app development projects and increase in equipment salesAnnual report
「[System Development and Maintenance] Although there were system development projects related to My Number in the securities business, system development for Gakken Group companies, and website renewal projects, revenue declined to ¥209.292 million, down 15.9% year on year, due to the loss of server replacement development projects in the securities business and tablet app development projects for medical systems. [Machine Sales] Sales of medical system equipment and other items resulted in revenue of ¥102.425 million, up 483.5% year on year.」
Although tablet app development projects for medical systems were lost, sales of medical system equipment rose to ¥102.425 million, up 483.5% year on year. - FY2022-Q3Loss of medical tablet development projects and increase in equipment salesAnnual report
「<System Development and Maintenance> Although there were system development projects related to My Number in the securities business and system development for Gakken Group companies, revenue declined to ¥149.909 million, down 23.0% year on year, due to the loss of server replacement development projects in the securities business and tablet app development projects for medical systems. <Machine Sales> Sales of medical system equipment and other items resulted in revenue of ¥56.298 million, up 607.9% year on year.」
In the medical field, tablet app development projects were lost, while sales of medical system equipment rose to ¥56.298 million, up 607.9% year on year. - FY2022-Q2Loss of medical tablet development projects and increase in equipment salesAnnual report
「<System development and maintenance> Sales were ¥107.574 million, down 5.6% year on year, despite My Number-related system development in securities operations and system development for Gakken Group companies, due mainly to the absence of application development projects for tablets used with medical systems. <Machinery sales> Sales were ¥47.798 million due mainly to sales of medical system equipment; the year-on-year change was not applicable.」
In the medical field, tablet app development projects were lost, while sales of medical system equipment were recognized. - FY2022-Q1Increase in sales of medical tablet productsAnnual report
「<Machine Sales> Sales of tablet products for medical systems and other items resulted in revenue of ¥6.150 million, up 237.4% year on year.」
In the medical field, sales of tablet products for medical systems increased 237.4% year on year. - FY2021Continued decline in medical business revenueAnnual report
「In general operations, revenue declined to ¥703.045 million, down 21.6% year on year, due to a decline in app development for tablets used in medical systems, a decline in operating services related to the clinical business resulting from the spread of COVID-19, and a decline in sales of tablet products for medical systems.」
The decline in app development and product sales for tablets used in medical systems, as well as operating services for the clinical business, continued, causing revenue from general operations to decline 21.6% year on year. - FY2021-Q3Continued decline in clinical operating servicesAnnual report
「During the cumulative third quarter under review, although the company deepened business with existing customers in the education business and had server replacement development projects in the securities business, revenue declined to ¥1,846.148 million, down 0.4% year on year, due mainly to a decline in operating services related to the clinical business resulting from the spread of COVID-19. Operating services related to the clinical business have generally progressed in line with the initial plan.」
Although there were server replacement projects in the securities business, the decline in operating services for the clinical business resulting from the spread of COVID-19 has continued. However, operating services for the clinical business have generally progressed in line with the initial plan. - FY2021-Q2Decline in medical app development and server projectsAnnual report
「During the cumulative second quarter under review, although there was app development for tablets used in medical systems, revenue declined to ¥938.881 million, down 10.3% year on year, due to the loss of interim acceptance in the education business in the previous fiscal year and a decline in operating services related to the clinical business resulting from the spread of COVID-19.」
Although app development for tablets used in medical systems was recognized, total revenue declined 10.3% year on year due mainly to a decline in operating services related to the clinical business. - FY2021-Q1Recognition of medical server replacement projects and decline in operating servicesAnnual report
「During the cumulative first quarter under review, although there was a server replacement development project related to the clinical business, revenue declined to ¥462.082 million, down 6.2% year on year, due to the loss of development projects for an unfair trading surveillance system in the securities business and a decline in operating services related to the clinical business resulting from the spread of COVID-19.」
In the medical field, a server replacement development project was recognized, while operating services for the clinical business declined due to the spread of COVID-19. - FY2020AdvancedAnnual report
「Although new contracts and an increase in the number of transactions in the education business, sales of tablet products for medical systems, app development, and operating services related to the clinical business increased, revenue declined to ¥5,151.966 million, down 3.5% year on year, due to the loss of system development projects related to the clinical business, the loss of development projects for SENS21, the securities comprehensive system, and the cancellation of administrative outsourcing services for securities companies.」
Sales of tablets for medical systems, app development and operating services for the clinical business increased, indicating the expansion of operations in the medical field from operations to development and product provision. - FY2020-Q2AdvancedAnnual report
「We have established the necessary structure based on our staffing plan to develop electronic medical records. We will work to accelerate business expansion and strengthen earnings capacity.」
To expand development of medical systems, the company established an operational structure based on its staffing plan. - FY2020-Q1Loss of medical-related development projectsAnnual report
「<System development and maintenance> Sales were ¥54.629 million, down 32.7% year on year, due mainly to the absence of system development for the Gakken Group and development related to the clinical testing business.」
Despite the policy of expanding medical-related operations, the disclosure reports the loss of system development projects related to the clinical laboratory business, resulting in a 32.7% year-on-year decline in system development and maintenance revenue. - FY2019RestatedAnnual report
「In medical-related operations, we have established a Medical Systems Section. We aim to expand entrusted medical system development projects in addition to system operations and will work steadily to accumulate expertise.」
The company continues its policy of using the Medical Systems Section as a base to expand from operations into medical system development projects, increase entrusted work and accumulate expertise. - FY2019-Q3AdvancedAnnual report
「In medical operations, electronic medical record implementation and development support also entered full-scale operation. To provide a major catalyst for expanding this business and maximize synergies, we established a Medical Systems Section.」
In medical systems, electronic medical record implementation and development support entered full-scale operation, and a Medical Systems Section was established to expand the business. - FY2019-Q2AdvancedAnnual report
「During the cumulative second quarter under review, the start of operations for new users of the SENS21 integrated securities system, electronic medical record implementation support and an increase in the number of My Number operational assignments were offset by the loss of financial services operations, and sales were broadly unchanged from the previous year.」
In medical operations, the disclosure describes progress into a specific service, namely support for electronic medical record implementation. - FY2019-Q1RestatedAnnual report
「Against this backdrop, the Group is pursuing various initiatives, with its medium-term management plan objective for fiscal 2018–2020 being to “take ODK to the next stage.” Its key priorities for the current fiscal year are “providing AI and HR tech services,” “responding to education reform, expanding medical operations, and optimizing head-office, branch-office and infrastructure functions,” and “promoting automation and outsourcing, and developing capabilities and skills.”」
The company has identified expansion of medical operations as a priority issue for the current year and continues its policy of expanding from medical system operations into development and deeper business engagement. - FY2018RestatedAnnual report
「In medical-related operations, we are participating not only in system operations but also in medical system development projects and working to deepen our business activities. We also aim to provide AI-powered solutions and accumulate expertise in the use of AI.」
The company continues its policy of expanding from medical system operations into participation in development projects and deeper business engagement, while aiming to provide AI solutions and accumulate expertise. - FY2018-Q3RestatedAnnual report
「During the cumulative third quarter under review, we continued to participate in medical system development projects through collaboration with FALCO HOLDINGS Co.,Ltd. and to pursue initiatives aimed at providing various AI-powered solutions, while actively working toward early monetization.」
The company continues to participate in medical system development projects through collaboration with FALCO HOLDINGS Co.,Ltd. and pursue initiatives aimed at providing AI solutions. - FY2018-Q2AdvancedAnnual report
「For the first six months of the current fiscal year, the company accelerated its efforts to participate in medical systems development projects in collaboration with FALCO HOLDINGS Co.,Ltd. and to provide various AI-based solutions in collaboration with リアルグローブ株式会社, actively working toward early monetization.」
In the medical field, which began with the operation of clinical laboratory systems, the disclosure describes concrete progress in participating in medical system development projects through collaboration with FALCO HOLDINGS Co.,Ltd. - FY2018-Q1RestatedAnnual report
「Against this backdrop, the Group is pursuing various initiatives, with its medium-term management plan objective for fiscal 2017–2019 being to transform itself into a “new ODK.” Its key priorities for the current fiscal year are “participation in medical systems development and provision of AI services,” “expanding sales of UCARO and My Number-related services,” and “thorough management of profitability by business and customer, and effective use of external resources.”」
Participation in medical system development has been restated as a priority issue for the current year under the FY2017–FY2019 plan. The policy of expanding from entrusted operation of clinical laboratory systems into participation in development continues. - FY2017First statedAnnual report
「Since June 2016, we have been entrusted with operating clinical laboratory systems. Going forward, we will participate in development as well as operations and seek to accumulate expertise in medical systems.」
The company explicitly states its policy of expanding from entrusted operation of clinical laboratory systems into participation in medical system development and the accumulation of expertise.